Nitromin, prepared by Stahmann and Bergmann (1946) was the first nitrogenmustard derivative to have a more marked growth-inhibiting effect on Yoshida sarcoma than nitrogen mustard itself, and to be of lesser toxicity (Ishidate, Kobayashi, Sakurai, Sato and Yoshida; cit. Farber et al., 1956) . In Japan, Nitromin is being widely used in human therapy. Kimura and his co-workers (cit. Farber et al., 1956) found that in addition to being of avail in cases of chronic leukaemia, it had a destructive effect on certain malignant tumours.
Another nitrogen-mustard derivative is Erysan (R48), an aromatic chloroethylamine, first synthesised by Haddow and his co-workers (1948) , which was shown to be highly effective on the Walker carcinosarcoma. Matthews (1950r eported its effectiveness in chronic myeloid and lymphoid leukaemia in humans, and Videbaek and Kaae (1954) in such cases of Hodgkin's disease as had failed to respond to X-ray treatment. Everett, Roberts, and Ross (1953) synthesised N,N-di-(2-chloroethyl)-paminophenyl-butyric acid, an aromatic nitrogen-mustard derivative, which they labelled CB 1348. This compound was found considerably to inhibit the growth of Walker tumours and according to Haddow (1954) , to have a beneficial effect on lymphoreticular tumours and haemoblastoses; its depressant effect on bone marrow was less than that of nitrogen mustard and TEM, respectively.
Larionov (1957) reported good results obtained with Sarcolysin and Dopan. Simultaneously with, but independently of Larionov and co-workers (1955) , Bergel and Stock (1954) also prepared sarcolysine dl-p-di(chloroethyl)-aminophenylalanine hydrochloride. It caused complete regression in two sarcomas of the rat and one of the mouse, and had a marked inhibitory effect on the growth of seven other mouse and rat tumours.
For some years Vargha has endeavoured to produce an agent of reduced toxicity, by linking nitrogen mustard with a sugar. Of the many compounds he has prepared 1,6-di-(2-chloroethylamino)-1,6-dideoxy-D-mannitol dihydrochloride has proved to be of good effect. Having been investigated in animal experiments by Kellner and N6meth (1956) and tested clinically by Sellei and Eckhardt (1958) , it has been introduced in human therapy as Degranol (BCM).
MATERIALS AND METHODS
Twenty-three combinations of nitrogen mustard with sugar, prepared by Vargha in the course of the last two years, were tested for their respective toxicity, and studied in transplantable animal tumours for their growth-inhibiting action.
Of these, one compound, marked R13, the structural formula of which may be represented as 1,6-di-(2-bromoethylamino)-1,6-dideoxy-D-mannitol dihydrobromide (DBM), was found to be the most promising (Vargha and Horvath, 1959; Balo6, Kendrey, Juhasz, Besznyak, 1959) . This is a stable compound readily soluble in water, of which 23 mg./kg. of body weight is the half-lethal dose (LD50) for the mouse, and 22 mg./kg. that for the rat.
Using Wistar strain rats and white mice of our own breed, experimentation in normal intact animals and animals with transplanted tumours showed the daily therapeutic dose level to vary between 1.5 and 3 mg./kg. for the tumourbearing rat, and 3 and 5 mg./kg. for the tumour-bearing mouse. In testing the compound against a spectrum of rat and mouse tumours, treatment, usually with daily intraperitoneal injections, was begun when the tumours were from a pea to a bean in size. A prolonged treatment not involving considerable loss of weight was aimed at. After treatment varying in time with the strain of tumour, the animals were killed, the tumours removed and measured, and the percentage growth-inhibition was determined on the basis of the following formula:
Average weight of tumours in controls-Average weight of Inhibition°t umours in experimentals x 100
Average weight of tumours in controls In some experiments survival time was used as a measure of benefit from the drug. In testing DBM against tumours in ascitic form, treatment was begun either one or two days after inoculation of the ascites, or on the first signs of ascites formation in the inoculated animal, and the degree of the inhibitory effect was graded according to the difference in body weight between the treated and the control animals.
The drug was subjected to detailed examinations for its effect on the blood picture, the bone marrow, and the parenchymatous organs.
In most cases the effectiveness of DBM was compared with that of Degranol (BCM).
RESULTS
Effect of DBM (R13) on transplantable tumours 1. The growth-inhibiting action on rat tumours was studied in a set of experiments using Guerin carcinoma, Benevolenskaya sarcoma, and a subcutaneous form of Yoshida sarcoma. In agreement with Druckrey and co-workers (1958), we found the latter was just as useful as Yoshida ascites sarcoma in testing chemotherapeutic agents: rats inoculated with the tumour in ascitic form survived for an average 8 to 10 days, with only 1 to 3 ml. of ascitic fluid forming; subcutaneously inoculated rats survived for 12 to 18 days.
The growth-inhibiting effect of DBM on the rat tumours involved in our experiments is illustrated in Table I and Fig. 1 In another experiment, in which animals bearing Ehrlich ascites tumours were treated during 9 days on each of seven occasions with 4-85 mg. of DBM per kg. of body weight, no ascites developed at all (Fig. 5) . Of Degranol, the same number of 21 mg. doses was required to achieve the identical effect. Effect of DBM on blood picture, bone marrow, and parenchymatous organs For its effect on peripheral blood DBM was studied in 16 rats of the Wistar strain, each weighing 150 g. After their complete blood pictures had been prepared, some normal animals were injected intraperitoneally on one occasion with a simple, others with a threefold, yet others with a tenfold medium therapeutic dose (the (Table III) . In animals given the medium therapeutic dose for 15 consecutive days, there was no change in the red cell count, but the white cells fell to 5000 per c.mm. from the normal of about 9000 per c.mm. generally counted in the control animals; in the number of lymphocytes a substantial decrease was observed; relative leukocytosis presented itself, associated with eosinophilia (Table IV) . For its action on bone marrow the compound was tested in normal intact Wistar strain rats which, in 45 days, had been treated on 34 occasions with 1.75 mg. of DBM per kg. of body weight by the intraperitoneal route. This treatment was followed by a slight decrease in the number of myeloid elements. In some individual cases the haemopoietic colonies were seen to have ceded their place to fatty bone marrow. The blood pictures of these animals revealed marked lymphopenia, relative leukocytosis, and moderate eosinophilia. No pathological changes were encountered in the myocardium, the lung, the kidney, and the adrenal gland, but the spleen was found to have decreased in size, and the lymph follicles were less than normal in number. Slight pulpar fibrosis was seen. In the liver parenchymatous degeneration was observed, but no fatty degeneration or cellular necrosis.
DISCUSSION
On the evidence of the results of our toxicity tests, the efficient but not toxic dose of DBM varies between 1.5 and 3.0 mg. per kg. of body weight for the tumour- bearing rat, and between 3 0 and 5 0 mg. for the tumour-bearing mouse. At these dose levels, the animals will stand treatment for 10 to 12 consecutive days without losing more than 6 to 12 per cent. in weight. The chemotherapeutic index for DBM being MTD MED --25, it comes to fall between that for Degranol (50) and nitrogen mustard (10).
From our experimental findings the conviction accrues that DBM is a drug, which exerts a marked inhibitory effect on tumour cells. Undoubtedly, it was the most effective against Yoshida sarcoma, a tumour responding as a rule fairly well to efficient chemotherapeutic agents. Equally remarkable was the effect it appeared to have on Guerin cancer, the more so as malignant animal tumours (Guerin and Ehrlich tumours) are conspicuous for the difficulty in influencing their growth by means of therapeutic drugs. Not a single complete regression was observed in animals inoculated with these tumours, unlike in cases of subcutaneously implanted Yoshida sarcoma. Histologically, the small tumours found in a few of our animals inoculated with Yoshida sarcoma and treated with DBM could no longer be regarded as real tumours.
In animals bearing Gu6rin or Ehrlich carcinoma, we on a few occasions succeeded in maintaining for some considerable period of time a state in which there was no perceptible tumour growth, and even several remissions took place. If in such a state treatment was continued, the animals died after a time, displaying toxic symptoms; if it was discontinued, the tumour started to grow again but could not be depressed once more, not even by means of larger doses.
With the histological changes in tumours following treatment with DBM, we propose to deal elsewhere.
SUMMARY
Twenty-three compounds prepared by linking nitrogen mustard with various sugars were tested on various transplantable tumours for their capacity to inhibit growth. The one designated as DBM (R13), the structural formula of which may be represented as 1,6-di-(2-bromoethylamino)-1,6-dideoxy-D-mannitol dihydrobromide, was found to have a marked inhibitory effect on Guerin rat carcinoma, subcutaneous form of Yoshida rat sarcoma, Benevolenskaya rat sarcoma, the subcutaneous and ascitic forms of Ehrlich mouse carcinoma, Crocker and S-37 mouse sarcoma, and Amytal ascites sarcoma in the mouse. The drug is much less toxic than nitrogen mustard and depresses tumour growth without causing considerable loss of weight or toxic side effects. It is not without effect on peripheral blood and the lymphatic organs. Following treatment with therapeutic doses for some longer period of time, there is a reduction first in the lymphocyte and then in the leukocyte count, the spleen diminishes in size, the lymph follicles in it grow less in number, and fibrosis of the pulp is seen. Animal experiments have shown this agent to be more effective than Degranol.
